Physician profile
James C Johnson
NPI 1821180514
$536.95
in general payments reported to CMS, 2019-2025
13 companies · $47.32 in 2025
The $47.32 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $102 · 2020: $87.31 · 2022: $96.77 · 2023: $166 · 2024: $37.99 · 2025: $47.32.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $251.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $251.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $90.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $75.00 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.19 | 2022-2023 | Lifevest |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.90 | 2022 | |
| Daxor Corporation | $49.69 | 2023 | Bva-100 |
| Amgen INC. | $40.40 | 2020-2025 | Repatha |
| Bracco Diagnostics INC. | $32.75 | 2023 | |
| Pfizer INC. | $29.84 | 2023 | |
| Nuwellis, INC. | $19.92 | 2024 | Aquadex Smartflow Console |
| Sumitomo Pharma America, INC. | $19.23 | 2025 | Gemtesa |
| Medtronic, INC. | $18.07 | 2024 | Corevalve Evolut R |
| Astellas Pharma US INC | $15.26 | 2022 | |
| Allergan, INC. | $11.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.